ACE-031 (ActRIIB Fusion Protein): A Laboratory Research Reference

ACE-031 is a soluble activin type IIB receptor (ActRIIB) fusion protein engineered to act as a decoy for myostatin and related ligands. It is studied in laboratory research for its influence on skeletal muscle signalling in experimental models.

This page is a non-promotional scientific reference for researchers. It summarises the chemical identity, molecular characteristics, mechanism as described in the literature, research areas, and analytical testing of ACE-031. It does not provide dosing, therapeutic, or human-use guidance of any kind. ACE-031 supplied by Bulk Aussie Peptides is for laboratory research purposes only.

What Is ACE-031?

ACE-031 is not a short peptide: it is a recombinant fusion protein in which the extracellular domain of the activin type IIB receptor (ActRIIB) is linked to the Fc region of an immunoglobulin. This design produces a soluble receptor that binds myostatin (growth differentiation factor-8) and related TGF-beta superfamily ligands such as activins and growth differentiation factors, sequestering them before they engage native cell-surface receptors.

For background on how research compounds are produced and verified, see the synthetic peptides research guide.

Molecular Characteristics

• Classification: a recombinant soluble ActRIIB-Fc fusion protein; a decoy receptor rather than a short peptide.
• Composition: the extracellular domain of activin type IIB receptor fused to an immunoglobulin Fc region.
• Molecular weight: a large dimeric, glycosylated protein exceeding 100 kDa; the measured value on a Certificate of Analysis should be interpreted against the documented form.
• Physical form: supplied as a lyophilised (freeze-dried) powder, the standard presentation for research material.

How ACE-031 Works

In laboratory models, ACE-031 binds soluble myostatin, activins, and related growth differentiation factors, preventing their interaction with native receptors and thereby reducing downstream SMAD signalling that normally restrains muscle growth. Because the ActRIIB receptor participates in the signalling of both myostatin and activin A, a receptor-decoy strategy is studied as a way to modulate several related ligands simultaneously. Research findings remain preclinical.

These observations describe receptor-ligand sequestration in model systems and do not constitute a therapeutic use.

Areas of Scientific Research

• Myostatin signalling: characterisation of myostatin and activin sequestration by the soluble receptor.
• Muscle biology: studies of muscle mass and fibre changes in experimental muscle models.
• Decoy-receptor design: comparison of ActRIIB decoys with other ligand-sequestering approaches.

These investigations are conducted in vitro or in approved animal research models under institutional oversight. They do not translate to approved human use.

Analytical Testing

• HPLC for purity and aggregate assessment.
• Mass spectrometry for identity confirmation, reflecting the glycosylated protein mass.

Guidance on reading the resulting documents is available in the article on how to read a peptide Certificate of Analysis.

Storage and Handling

In a laboratory context, lyophilised ACE-031 is typically stored in a freezer, protected from light and moisture, and handled according to the product-specific documentation. General guidance is covered in the peptide storage and stability reference.

Frequently Asked Questions

• Is ACE-031 a peptide? No — it is a recombinant fusion protein (soluble ActRIIB receptor fused to an Fc region).
• What does ACE-031 target? It acts as a decoy for myostatin and related TGF-beta superfamily ligands.
• How does ACE-031 differ from a myostatin antibody? Antibodies bind a single ligand, whereas the ActRIIB decoy can bind multiple related ligands.
• What is ACE-031 studied for? It is investigated in laboratory models for muscle signalling and myostatin pathway modulation.
• How is ACE-031 purity tested? By HPLC with identity confirmed by mass spectrometry.

References

• Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson, K. N., et al. (2005). Regulation of muscle growth by multiple ligands signaling through activin type II receptors. Proceedings of the National Academy of Sciences, 102(50), 18117–18122. PubMed 16330774

Related Research Resources

• IGF-1 LR3: A Laboratory Research Reference — a related muscle-signalling compound.
• Synthetic Peptides: Research Guide — how research compounds are produced and verified.